
Diabetes Dialogue: FDA Clearance of Tidepool Loop
In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.
As advancing technology continues to push patient care into the future, a new emphasis has been placed on creating technologies with the ability to be customized and precise to each patient. There may be no fields where this is more evident than in diabetes technologies, where breakthroughs seem to occur on a regular basis and, earlier this month, a
Named Tidepool Loop, the prescription-only mobile app, which was created by Tidepool, received clearance from the FDA for use with compatible devices for automated insulin dosing to help manage
To celebrate the historic clearance and provide real-world perspective on what it means for people with type 1 diabetes, Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the CGM Program at the Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner with R&B Medical Group, tackle the clearance of the Tidepool Loop in this special edition episode of
All episodes of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives are available in an audio-only format on










































































